From Patient-Derived GBM Tumoroids to Multi-Indication Clinical Development
We are honored by Aveta Biomics' recognition of Sapien's contribution to their drug development efforts. It is especially gratifying to see our patient-derived models and New Approach Methodologies (NAMs) delivering meaningful translational insights and helping advance a promising therapeutic program toward Phase III clinical development. At Sapien, our mission is to bridge human biology and therapeutic innovation, and we are encouraged to see these approaches contributing to more informed development decisions. We congratulate the Aveta team on this important milestone, and look forward to continuing our collaboration to improve treatment options and outcomes for cancer patients.
We are honored by Aveta Biomics' recognition of Sapien's contribution to their drug development efforts. It is especially gratifying to see our patient-derived models and New Approach Methodologies (NAMs) delivering meaningful translational insights and helping advance a promising therapeutic program toward Phase III clinical development.
At Sapien, our mission is to bridge human biology and therapeutic innovation, and we are encouraged to see these approaches contributing to more informed development decisions. We congratulate the Aveta team on this important milestone, and look forward to continuing our collaboration to improve treatment options and outcomes for cancer patients.
- No tags were found...
Transform your PDFs into Flipbooks and boost your revenue!
Leverage SEO-optimized Flipbooks, powerful backlinks, and multimedia content to professionally showcase your products and significantly increase your reach.
Client Spotlight
From Patient-Derived GBM Tumoroids to Multi-
Indication Clinical Development
HOW SAPIEN BIOSCIENCES SUPPORTED
PRECLINICAL EVALUATION THAT CONTRIBUTED
TO THE ADVANCEMENT OF A THERAPEUTIC
PROGRAM ACROSS MULTIPLE INDICATIONS.
READ MORE
Early translational validation using Sapien’s
human patient-centric 2D and 3D tumor models
In 2018, Aveta Biomics partnered with
Sapien Biosciences to evaluate APG-157,
our lead therapeutic candidate, using
patient-derived cancer (PDC) assays and
clinically relevant 3D tumoroid models
generated from human glioblastoma
(GBM) tumor tissues.
Translational Data Supporting Development
Decisions
The studies conducted by Sapien generated translational
efficacy data demonstrating anti-tumor activity in patientderived
GBM models, human patient-derived systems
designed to better reflect the tumor microenvironment and
clinical biology. This dataset has contributed to regulatory
submissions and investor discussions supporting our GBM
program and continues to be utilized to demonstrate APG-
157's broader anti-cancer potential as the molecule
advances across multiple oncology indications.
Early Adoption of Human-Relevant NAMs
Sapien's patient-centric 2D and 3D assay platforms
represented an early implementation of human-relevant
New Approach Methodologies (NAMs), enabling clinically
meaningful translational insights beyond traditional
preclinical models. The ability to evaluate therapeutic
response directly in patient-derived GBM tumoroids
provided valuable evidence supporting the mechanism,
efficacy, and the drug's potential across oncology.
Advancing Across Multiple Oncology Indications
APG-157 has since advanced into Phase 2 clinical
development in GBM and is also entering global Phase III
clinical development in head and neck squamous cell
carcinoma (HNSCC) with a recent podium presentation at
AHNS, a leading global head and neck oncology conference.
The mechanism of action is found to be common between
GBM and HNSCC. As Aveta's multi-indication clinical
programs continue to advance internationally, there is strong
interest in expanding our collaboration with Sapien into
HNSCC and additional oncology indications using their
evolving patient-derived assay platforms.
DEVELOPMENT JOURNEY &
SCIENTIFIC IMPACT STORY
2018
Partnership
Patientderived
GBM
Tumoroids
Translational
Efficacy Data
Regulatory
&
Investor
Support
Phase II GBM
Global
Phase III
HNSCC
Expanded
Collaboration
Interest
2018 → Today → Beyond
Jugnu Jain, PhD.
CEO, Sapien Biosciences
Parag G. Mehta, PhD.
CEO, Aveta Biomics
A partnership built on science and
shared vision
From Discovery
to
Clinical Impact
Change language